Skip to main content
Top
Published in: Journal of General Internal Medicine 4/2011

Open Access 01-04-2011 | Original Research

Chronic Kidney Disease and the Risk of End-Stage Renal Disease versus Death

Authors: Lorien S. Dalrymple, MD, MPH, Ronit Katz, DPhil, Bryan Kestenbaum, MD, MS, Michael G. Shlipak, MD, MPH, Mark J. Sarnak, MD, MS, Catherine Stehman-Breen, MD, MS, Stephen Seliger, MD, MS, David Siscovick, MD, MPH, Anne B. Newman, MD, MPH, Linda Fried, MD, MPH

Published in: Journal of General Internal Medicine | Issue 4/2011

Login to get access

ABSTRACT

BACKGROUND

Among older adults with chronic kidney disease (CKD), the comparative event rates of end-stage renal disease (ESRD) and cause-specific death are unknown.

OBJECTIVE

To compare the rates of ESRD, cardiovascular and non-cardiovascular death and examine risk factors for ESRD and all-cause mortality in Cardiovascular Health Study (CHS) participants.

Design

The CHS is a longitudinal cohort study of community-dwelling adults aged 65 years and older.

PARTICIPANTS

1,268 participants with an estimated glomerular filtration rate (eGFR) < 60 ml/min per 1.73 m2 were followed until the time of first event (ESRD, cardiovascular or non-cardiovascular death) or until March 31, 2003.

MAIN MEASURES

The outcomes were ESRD, cardiovascular- and non-cardiovascular death. Rates of each event were calculated, and a Cox Proportional Hazards Model with a competing risk framework was used to examine risk factors for ESRD as compared with death. Predictors included age, gender, race, BMI, hypertension, diabetes, cardiovascular disease, heart failure, tobacco use, eGFR, and total cholesterol.

KEY RESULTS

During 9.7 years of follow-up, 5% of the cohort progressed to ESRD, and 61% of the cohort died. The rate (per 100 person-years) was 0.5 for ESRD and 6.8 for all-cause mortality (3.0 for cardiovascular and 3.8 for non-cardiovascular mortality). In the competing risk framework, lower eGFR, male gender, African-American race, and higher BMI were associated with an increased risk of ESRD.

CONCLUSIONS

Older adults with CKD are 13-fold more likely to die from any cause than progress to ESRD and are 6-fold more likely to die from cardiovascular causes than develop ESRD.
Literature
1.
go back to reference Lesley AS, Suying L, Changchun W, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: Results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010;55(3):S23–S33.CrossRef Lesley AS, Suying L, Changchun W, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: Results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010;55(3):S23–S33.CrossRef
2.
go back to reference Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–63.PubMedCrossRef Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–63.PubMedCrossRef
3.
go back to reference Peralta CA, Shlipak MG, Fan D, et al. Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2892–9.PubMedCrossRef Peralta CA, Shlipak MG, Fan D, et al. Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2892–9.PubMedCrossRef
4.
go back to reference Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489–95.PubMedCrossRef Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489–95.PubMedCrossRef
5.
go back to reference Wan H, Sengupta M, Velkoff VA, and DeBarros KA. US Census Bureau, Current Population Reports, 65+ in the United States: 2005, US Government Printing Office, Washington, DC, 2005.23-209. Wan H, Sengupta M, Velkoff VA, and DeBarros KA. US Census Bureau, Current Population Reports, 65+ in the United States: 2005, US Government Printing Office, Washington, DC, 2005.23-209.
6.
go back to reference Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–2047.PubMedCrossRef Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–2047.PubMedCrossRef
7.
go back to reference Fried LF, Katz R, Sarnak MJ, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol. 2005;16(12):3728–3735.PubMedCrossRef Fried LF, Katz R, Sarnak MJ, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol. 2005;16(12):3728–3735.PubMedCrossRef
8.
go back to reference Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.PubMedCrossRef Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.PubMedCrossRef
9.
go back to reference Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049–60.PubMedCrossRef Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049–60.PubMedCrossRef
10.
go back to reference Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1(3):263–76.PubMedCrossRef Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1(3):263–76.PubMedCrossRef
11.
go back to reference Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol. 1993;3(4):358–66.PubMedCrossRef Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol. 1993;3(4):358–66.PubMedCrossRef
12.
go back to reference Ives DG, Fitzpatrick AL, Bild DE, et al. Surveillance and ascertainment of cardiovascular events: The Cardiovascular Health Study. Ann Epidemiol. 1995;5(4):278–285.PubMedCrossRef Ives DG, Fitzpatrick AL, Bild DE, et al. Surveillance and ascertainment of cardiovascular events: The Cardiovascular Health Study. Ann Epidemiol. 1995;5(4):278–285.PubMedCrossRef
13.
go back to reference Psaty BM, Kuller LH, Bild D, et al. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol. 1995;5(4):270–277.PubMedCrossRef Psaty BM, Kuller LH, Bild D, et al. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol. 1995;5(4):270–277.PubMedCrossRef
14.
go back to reference Ives DG. Agreement Between Nosologist and Cardiovascular Health Study Review of Deaths: Implications of Coding Differences. J Am Geriatri Soc. 2009;57(1):133–139.CrossRef Ives DG. Agreement Between Nosologist and Cardiovascular Health Study Review of Deaths: Implications of Coding Differences. J Am Geriatri Soc. 2009;57(1):133–139.CrossRef
15.
go back to reference Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;41(2):264–70.PubMed Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;41(2):264–70.PubMed
16.
go back to reference Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15(5):1307–1315.PubMedCrossRef Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15(5):1307–1315.PubMedCrossRef
17.
go back to reference National Kidney Foundation, Inc. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease. Am J Kidney Dis. 2002;39(2):S76-S110. National Kidney Foundation, Inc. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease. Am J Kidney Dis. 2002;39(2):S76-S110.
18.
go back to reference Fine JP, Gray RJ. A Proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.CrossRef Fine JP, Gray RJ. A Proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.CrossRef
19.
go back to reference O'Hare AM, Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol. 2007;18(10):2758–2765.PubMedCrossRef O'Hare AM, Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol. 2007;18(10):2758–2765.PubMedCrossRef
20.
go back to reference Menon V, Wang X, Sarnak MJ, et al. Long-term outcomes in nondiabetic chronic kidney disease. Kidney Int. 2008;73(11):1310–5.PubMedCrossRef Menon V, Wang X, Sarnak MJ, et al. Long-term outcomes in nondiabetic chronic kidney disease. Kidney Int. 2008;73(11):1310–5.PubMedCrossRef
21.
go back to reference Levin A, Djurdjev O, Beaulieu M, Er L. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis. 2008;52(4):661–71.PubMedCrossRef Levin A, Djurdjev O, Beaulieu M, Er L. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis. 2008;52(4):661–71.PubMedCrossRef
22.
go back to reference Agarwal R, Bunaye Z, Bekele DM, Light RP. Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease. Am J Nephrol. 2008;28(4):569–75.PubMedCrossRef Agarwal R, Bunaye Z, Bekele DM, Light RP. Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease. Am J Nephrol. 2008;28(4):569–75.PubMedCrossRef
23.
go back to reference Sekkarie MA, Moss AH. Withholding and withdrawing dialysis: The role of physician specialty and education and patient functional status. Am J Kidney Dis. 1998;31(3):464–472.PubMedCrossRef Sekkarie MA, Moss AH. Withholding and withdrawing dialysis: The role of physician specialty and education and patient functional status. Am J Kidney Dis. 1998;31(3):464–472.PubMedCrossRef
24.
go back to reference Diehr P, Bild DE, Harris TB, Duxbury A, Siscovick D, Rossi M. Body mass index and mortality in nonsmoking older adults: the Cardiovascular Health Study. Am J Public Health. 1998;88(4):623–629.PubMedCrossRef Diehr P, Bild DE, Harris TB, Duxbury A, Siscovick D, Rossi M. Body mass index and mortality in nonsmoking older adults: the Cardiovascular Health Study. Am J Public Health. 1998;88(4):623–629.PubMedCrossRef
25.
go back to reference Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA. 1998;279(8):585–92.PubMedCrossRef Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA. 1998;279(8):585–92.PubMedCrossRef
Metadata
Title
Chronic Kidney Disease and the Risk of End-Stage Renal Disease versus Death
Authors
Lorien S. Dalrymple, MD, MPH
Ronit Katz, DPhil
Bryan Kestenbaum, MD, MS
Michael G. Shlipak, MD, MPH
Mark J. Sarnak, MD, MS
Catherine Stehman-Breen, MD, MS
Stephen Seliger, MD, MS
David Siscovick, MD, MPH
Anne B. Newman, MD, MPH
Linda Fried, MD, MPH
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 4/2011
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-010-1511-x

Other articles of this Issue 4/2011

Journal of General Internal Medicine 4/2011 Go to the issue

Innovations and Improvement: Improvement Happens

Improvement Happens: An Interview with David Judge, MD

Healing Arts: Materia Medica

A Death in Primary Care

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.